glp 1 and kidneys does help with kidney disease Glucagon-like peptide-1 receptor signaling modifies the extent of diabetic through dampening the receptor for Efficacy and safety of incretin

National Glycohemoglobin Standardization Program (NGSP) Steering Committee

The FLOW trial, a double-blind, placebo-controlled study examining renal outcomes in patients with type 2 diabetes and chronic kidney disease, demonstrated that semaglutide reduced the progression of kidney disease by 24% compared to placebo

The ongoing dedicated ophthalmic trial named as FOCUS study, which aims to evaluate semaglutides long-term effects on diabetic retinopathy, is now ongoing and could contribute to a comprehensive understanding of the true risk-benefit profile of these agents in patients with or at risk for diabetic retinopathy (NCT03811561) [104]

43 , e13065